IDiyas

For the Inventor, By the Inventor

Brier, WA, United States of America

Alistair J Leigh

USPTO Granted Patents = 15

Average Co-Inventor Count = 3.4

ph-index = 7

Forward Citations = 186(Granted Patents)


Location History:

  • Edmonds, WA (US) (1994 - 1995)
  • Brier, WA (US) (1996 - 2000)

Company Filing History:

goldMedal15 out of 103 
 
Cell Therapeutics, Inc.
 patents

Years Active: 1994-2000

Loading Chart...
15 patents (USPTO):Explore Patents
1. 6121270 - Epoxide-containing compounds (2000-09-19),
2. 6100271 - Therapeutic compounds containing xanthinyl (2000-08-08),
3. 6043250 - Methods for using therapeutic compounds containing xanthinyl (2000-03-28),
4. 6020337 - Electronegative-substituted long chain xanthine compounds (2000-02-01),
5. 5889011 - Substituted amino alkyl compounds (1999-03-30),
6. 5866576 - Epoxide-containing compounds (1999-02-02),
7. 5817662 - Substituted amino alkyl compounds (1998-10-06),
8. 5807862 - Therapeutic compounds containing pyrimidinyl moieties (1998-09-15),
9. 5777115 - Acetal-and ketal-substituted pyrimidine compounds (1998-07-07),
10. 5770595 - Oxime substituted therapeutic compounds (1998-06-23),
11. 5670506 - Halogen, isothiocyanate or azide substituted xanthines (1997-09-23),
12. 5629423 - Asymmetric synthesis of chiral secondary alcohols (1997-05-13),
13. 5521315 - Olefin substituted long chain compounds (1996-05-28),
14. 5440041 - Acetal or ketal substituted xanthine compounds (1995-08-08),
15. 5340813 - Substituted aminoalkyl xanthine compounds (1994-08-23),

Title: Alistair J Leigh: Innovator in Pharmaceutical Chemistry

Introduction

Alistair J Leigh, based in Brier, Washington, is a prominent inventor known for his significant contributions to pharmaceutical chemistry. With a total of 15 patents to his name, he has demonstrated his commitment to advancing medical science through innovative solutions.

Latest Patents

Among his most recent patents, Leigh has developed novel epoxide-containing compounds. These compounds encompass enantiomers, diastereomers, salts, solvates, hydrates, and mixtures, characterized by a flexible core moiety that can be either non-cyclic or part of a five- to seven-membered ring. This specific design allows for a variety of functional groups, enhancing their applicability in treating diseases or managing treatment-induced toxicity, which is mediated by second messenger activity. Additionally, he has patented therapeutic compounds containing xanthinyl, featuring at least one carboxylic acid, ester, or amide-substituted side chain, presenting new avenues for pharmaceutical applications.

Career Highlights

Leigh is currently associated with Cell Therapeutics, Inc., where he plays a crucial role in developing innovative therapies aimed at improving patient outcomes. His extensive background in pharmaceutical research underpins his ability to create impactful inventions within the industry.

Collaborations

Throughout his career, Leigh has collaborated with esteemed colleagues, including Gail E Underiner and J Peter Klein. These collaborations have fostered an environment of innovation, allowing for the exchange of ideas and advancements in the pharmaceutical landscape.

Conclusion

Alistair J Leigh's contributions to pharmaceutical chemistry have made a significant impact on medical research. With a portfolio of 15 patents, his work continues to inspire and pave the way for future advancements in treatment methodologies. As an inventor, he exemplifies the spirit of innovation that drives the industry forward.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…